Herpes zoster surveillance using electronic databases in the Valencian Community (Spain)

BMC Infectious Diseases

Lina Pérez-Breva¹  Sara Alemán-Sánchez¹  Joan Puig-Barberá¹  Sergio Martínez-Úbeda¹  Javier Diez-Domingo¹  Nuria Morant-Talamante¹ 

[1] Vaccine Research Area, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region FISABIO - Public Health, Valencia, Spain

关键词: Spain;    Electronic health record;    Epidemiology;    Herpes Zoster;   

Others  :  1145710
DOI  :  10.1186/1471-2334-13-463

 received in 2013-03-25, accepted in 2013-09-18,  发布年份 2013

【 摘 要 】

Background

Epidemiologic data of Herpes Zoster (HZ) disease in Spain are scarce. The objective of this study was to assess the epidemiology of HZ in the Valencian Community (Spain), using outpatient and hospital electronic health databases.

Methods

Data from 2007 to 2010 was collected from computerized health databases of a population of around 5 million inhabitants. Diagnoses were recorded by physicians using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). A sample of medical records under different criteria was reviewed by a general practitioner, to assess the reliability of codification.

Results

The average annual incidence of HZ was 4.60 per 1000 persons-year (PY) for all ages (95% CI: 4.57-4.63), is more frequent in women [5.32/1000PY (95% CI: 5.28-5.37)] and is strongly age-related, with a peak incidence at 70-79 years. A total of 7.16/1000 cases of HZ required hospitalization.

Conclusions

Electronic health database used in the Valencian Community is a reliable electronic surveillance tool for HZ disease and will be useful to define trends in disease burden before and after HZ vaccine introduction.

【 授权许可】

   
2013 Morant-Talamante et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Johnson RW: Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines 2010, 9(3 Suppl):21-26.
• [2]Johnson RW, McElhaney J: Postherpetic neuralgia in the elderly. Int J Clin Pract 2009, 63(9):1386-1391.
• [3]Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al.: The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 2010, 182(16):1731-1736.
• [4]Dworkin RH, Gnann JW, Oaklander AL, Raja SN, Schmader KE, Whitley RJ: Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008, 9(1 Suppl 1):S37-S44.
• [5]Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, et al.: Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine 2012, 30(12):2047-2050.
• [6]Lukas K, Edte A, Bertrand I: The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Z Gesundh Wiss 2012, 20(4):441-451.
• [7]Plotkin SAOW, Offit PA: Vaccines. 5th edition. Philadelphia: Saunders Elsevier; 2008.
• [8]Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS: A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007, 82(11):1341-1349.
• [9]Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, et al.: Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother 2013, 9(5):1177-1184.
• [10]Schmader K: Herpes zoster in older adults. Clin Infect Dis 2001, 32(10):1481-6.
• [11]Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW: Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013, 13:170. BioMed Central Full Text
• [12]Thomas SL, Hall AJ: What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004, 4(1):26-33.
• [13]European Commission: Europe’s demographic future: Facts and figures on challenges and opportunities. Directorate-General for Employment, Social Affairs and Equal Opportunities; 2012. http://ec.europa.eu/social/BlobServlet?docId=1540&langId=en webcite
• [14]Aw D, Silva AB, Palmer DB: Immunosenescence: emerging challenges for an ageing population. Immunology 2007, 120(4):435-46.
• [15]Salleras M, Domínguez A, Soldevila N, Prat A, Garrido P, Torner N, et al.: Contacts with children and young people and adult risk of suffering herpes zoster. Vaccine 2011, 29(44):7602-5.
• [16]Thomas SL, Wheeler JG, Hall AJ: Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002, 360(9334):678-82.
• [17]Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, et al.: The incidence of varicella and herpes zoster in Massachusetts as measured by the behavioral risk factor surveillance system (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005, 5:68. BioMed Central Full Text
• [18]Guzzetta G, Poletti P, Del Fava E, Ajelli M, Scalia Tomba GP, Merler S, et al.: Hope-Simpson’s progressive immunity hypothesis as a possible explanation for herpes zoster incidence data. Am J Epidemiol 2013, 177(10):1134-42.
• [19]Bennett GJ, Watson CP: Herpes zoster and postherpetic neuralgia: past, present and future. Pain Res Manag 2009, 14(4):275-82.
• [20]Karhunen M, Leino T, Salo H, Davidkin I, Kilpi T, Auranen K: Modelling the impact of varicella vaccination on varicella and zoster. Epidemiol Infect 2010, 138(4):469-81.
• [21]Brisson M, Gay NJ, Edmunds WJ, Andrews NJ: Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002, 20(19–20):2500-7.
• [22]van Hoek AJ, Melegaro A, Zagheni E, Edmunds WJ, Gay N: Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. Vaccine 2011, 29(13):2411-20.
• [23]Gao Z, Gidding HF, Wood JG, MacIntyre CR: Modelling the impact of one-dose vs. two-dose vaccination regimens on the epidemiology of varicella zoster virus in Australia. Epidemiol Infect 2010, 138(4):457-68.
• [24]Gaillat J, Gajdos V, Launay O, Malvy D, Demoures B, Lewden L, et al.: Does monastic life predispose to the risk of Saint Anthony’s fire (herpes zoster)? Clin Infect Dis 2011, 53(5):405-10.
• [25]Poletti P, Melegaro A, Ajelli M, Del Fava E, Guzzetta G, Faustini L, et al.: Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries. PLoS One 2013, 8(4):e60732.
• [26]Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF: Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005, 191(12):2002-7.
• [27]Asociación Española de Pediatría: Documento en relación al calendario único de vacunaciones y las vacunas disponibles en España. 2013. http://vacunasaep.org/sites/vacunasaep.org/files/AEP-vacunas-y-calendario-vacunal-unico_0.pdf webcite
• [28]Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al.: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352(22):2271-84.
• [29]Schmader KE, Levin MJ, Gnann JW, McNeil SA, Vesikari T, Betts RF, et al.: Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012, 54(7):922-8.
• [30]Langan SM, Smeeth L, Margolis DJ, Thomas SL: Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med 2013, 10(4):e1001420.
• [31]European Medicines Agency: European Public Assessment Report (EPAR) for ZOSTAVAX summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000674/WC500053462.pdf webcite
• [32]Study to Evaluate GSK Biologicals’ Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 70 Years: ClinicalTrails.gov. 2012. http://clinicaltrials.gov/ct2/show/NCT01165229?term=zoster&rank=1 webcite
• [33]Study to Evaluate GSK Biologicals’ Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years: ClinicalTrials.gov. 2012. http://clinicaltrials.gov/ct2/show/NCT01165177?term=zoster&rank=14 webcite
• [34]Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, et al.: A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012, 206(8):1280-90.
• [35]Cebrián-Cuenca AM, Díez-Domingo J, Rodríguez MS, Puig-Barberá J, Navarro-Pérez J: Community’ HZRGotV. Epidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian community (Spain). BMC Fam Pract 2010, 11:33. BioMed Central Full Text
• [36]Cebrián-Cuenca AM, Díez-Domingo J, San-Martín-Rodríguez M, Puig-Barberá J, Navarro-Pérez J: Community HZRGotV. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. BMC Infect Dis 2011, 11:302. BioMed Central Full Text
• [37]Instituto Nacional de Estadística: Cifras oficiales de población resultantes de la revisión del Padrón municipal a 1 de enero de 2011. 2012. http://www.ine.es/jaxi/tabla.do?path=/t20/e260/a2011/l0/&file=ccaa01.px&type=pcaxis&L=0 webcite
• [38]Indra Sistemas SA: Proyecto Abucasis Conselleria Sanitat Valencia. 2012. http://www.indracompany.com/sectores/sanidad/proyectos/179/proyecto-abucasis-conselleria-de-sanitat-valencia webcite
• [39]España. Ministerio de Sanidad y Política Social: Las TIC en el Sistema Nacional de Salud : el programa Sanidad en línea: actualización de datos enero 2010. Madrid: Red.es; 2010:24. Available from: http://www.msssi.gob.es/profesionales/hcdsns/TICS/TICS_SNS_ACTUALIZACION_ES_2010.pdf webcite
• [40]Puig-Barberà J, Natividad-Sancho A, Calabuig-Pérez J, Lluch-Rodrigo JA, Pastor-Villalba E, Martínez-Úbeda S, et al.: MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. Vaccine 2013, 31:3995-4002.
• [41]Gil A, Gil R, Alvaro A, San Martín M, González A: Burden of herpes zoster requiring hospitalization in Spain during a seven-year period (1998-2004). BMC Infect Dis 2009, 9:55. BioMed Central Full Text
• [42]García Cenoz M, Castilla J, Montes Y, Morán J, Salaberri A, Elía F, et al.: Varicella and herpes zoster incidence prior to the introduction of systematic child vaccination in Navarre, 2005-2006. An Sist Sanit Navar 2008, 31(1):71-80.
• [43]Pérez-Farinós N, Ordobás M, García-Fernández C, García-Comas L, Cañellas S, Rodero I, et al.: Varicella and herpes zoster in Madrid, based on the sentinel general practitioner network: 1997-2004. BMC Infect Dis 2007, 7:59. BioMed Central Full Text
• [44]Gil A, San-Martín M, Carrasco P, González A: Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine 2004, 22(29–30):3947-3951.
• [45]Peña-Rey I, de Aragón MV M, Villaverde Hueso A, Terres Arellano M, Alcalde Cabero E, Suárez Rodríguez B: [Epidemiology of varicella in spain pre-and post-vaccination periods]. Rev Esp Salud Publica 2009, 83(5):711-24.
• [46]Chiappe SG, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, et al.: Herpes zoster: Burden of disease in France. Vaccine 2010, 28(50):7933-8.
• [47]Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, et al.: Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis 2010, 10:230. BioMed Central Full Text
• [48]de Melker H, Berbers G, Hahné S, Rümke H, van den Hof S, de Wit A, et al.: The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006, 24(18):3946-52.
• [49]Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O: Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis 2011, 11:173. BioMed Central Full Text
• [50]Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F: Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis 2011, 52(3):332-40.
• [51]Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ: Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011, 305(2):160-6.
• [52]Oxman MN: Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc 2009, 109(6 Suppl 2):S13-7.
• [53]Hope-Simpson RE: The Nature of Herpes Zoster: A long-term study and a new hypothesis. Proc R Soc Med 1965, 58:9-20.
• [54]van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE: Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res 2010, 10:237. BioMed Central Full Text
• [55]Bilcke J, Ogunjimi B, Marais C, de Smet F, Callens M, Callaert K, et al.: The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect 2012, 140(11):2096-109.
• [56]Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J: The burden of Herpes Zoster: a prospective population based study. Vaccine 2006, 24(9):1308-14.